| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 72 | 2026 | 849 | 11.730 |
Why?
|
| Down Syndrome | 27 | 2025 | 233 | 6.910 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2024 | 156 | 2.640 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2025 | 91 | 2.360 |
Why?
|
| Leukemia, Myeloid, Acute | 12 | 2026 | 578 | 2.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 1356 | 1.590 |
Why?
|
| Leukemia | 6 | 2023 | 375 | 1.350 |
Why?
|
| Methotrexate | 11 | 2025 | 342 | 1.330 |
Why?
|
| Child | 97 | 2026 | 26250 | 1.290 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2025 | 187 | 1.080 |
Why?
|
| Child, Preschool | 48 | 2026 | 15054 | 0.930 |
Why?
|
| Antineoplastic Agents | 9 | 2026 | 1810 | 0.910 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1277 | 0.900 |
Why?
|
| Philadelphia Chromosome | 3 | 2024 | 43 | 0.890 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 35 | 0.870 |
Why?
|
| Disease-Free Survival | 16 | 2024 | 910 | 0.870 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 2 | 0.820 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2023 | 35 | 0.810 |
Why?
|
| Humans | 121 | 2026 | 131604 | 0.810 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 66 | 0.800 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 120 | 0.800 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2026 | 142 | 0.800 |
Why?
|
| Prognosis | 27 | 2026 | 4952 | 0.790 |
Why?
|
| Infant | 36 | 2026 | 13305 | 0.770 |
Why?
|
| Neoplasm, Residual | 6 | 2023 | 136 | 0.740 |
Why?
|
| Adolescent | 44 | 2026 | 20931 | 0.740 |
Why?
|
| Penetrance | 1 | 2020 | 116 | 0.640 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 1263 | 0.620 |
Why?
|
| Lymphoma | 1 | 2023 | 330 | 0.610 |
Why?
|
| Integrases | 1 | 2020 | 158 | 0.610 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 174 | 0.610 |
Why?
|
| Receptors, Cytokine | 4 | 2024 | 64 | 0.610 |
Why?
|
| Self Report | 2 | 2026 | 558 | 0.600 |
Why?
|
| Male | 66 | 2026 | 65228 | 0.570 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2026 | 2862 | 0.570 |
Why?
|
| Mycoses | 2 | 2021 | 110 | 0.560 |
Why?
|
| Gene Rearrangement | 4 | 2024 | 323 | 0.530 |
Why?
|
| Female | 65 | 2026 | 71145 | 0.530 |
Why?
|
| Salvage Therapy | 1 | 2019 | 178 | 0.530 |
Why?
|
| Acute Disease | 8 | 2023 | 1153 | 0.500 |
Why?
|
| Young Adult | 22 | 2025 | 10094 | 0.480 |
Why?
|
| Metabolome | 3 | 2025 | 329 | 0.460 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 825 | 0.460 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 529 | 0.460 |
Why?
|
| Janus Kinase 2 | 4 | 2017 | 139 | 0.440 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2025 | 3412 | 0.440 |
Why?
|
| Genome-Wide Association Study | 7 | 2025 | 1840 | 0.440 |
Why?
|
| Remission Induction | 2 | 2012 | 309 | 0.430 |
Why?
|
| Recurrence | 9 | 2024 | 1483 | 0.430 |
Why?
|
| Metabolomics | 3 | 2025 | 493 | 0.430 |
Why?
|
| Transcription Factors | 3 | 2020 | 2436 | 0.420 |
Why?
|
| Mutation | 9 | 2023 | 6177 | 0.400 |
Why?
|
| Induction Chemotherapy | 2 | 2025 | 55 | 0.380 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1833 | 0.380 |
Why?
|
| Steroids | 1 | 2013 | 172 | 0.370 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 265 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2014 | 326 | 0.340 |
Why?
|
| Gene Deletion | 3 | 2021 | 773 | 0.340 |
Why?
|
| Treatment Failure | 1 | 2012 | 353 | 0.340 |
Why?
|
| Chromosome Aberrations | 4 | 2023 | 577 | 0.330 |
Why?
|
| DNA Methylation | 3 | 2021 | 1085 | 0.330 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2463 | 0.330 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 236 | 0.320 |
Why?
|
| Health Status Disparities | 2 | 2026 | 278 | 0.320 |
Why?
|
| Genomics | 5 | 2024 | 1624 | 0.300 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 5 | 0.300 |
Why?
|
| Dasatinib | 2 | 2020 | 53 | 0.290 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 299 | 0.270 |
Why?
|
| Histones | 1 | 2011 | 518 | 0.270 |
Why?
|
| Point Mutation | 1 | 2008 | 339 | 0.270 |
Why?
|
| Acute Kidney Injury | 2 | 2026 | 686 | 0.260 |
Why?
|
| Risk Factors | 13 | 2026 | 10959 | 0.260 |
Why?
|
| Residence Characteristics | 2 | 2020 | 292 | 0.260 |
Why?
|
| Neoplasms | 5 | 2024 | 2969 | 0.250 |
Why?
|
| Case-Control Studies | 9 | 2026 | 3454 | 0.240 |
Why?
|
| Mice | 12 | 2025 | 18486 | 0.240 |
Why?
|
| Nondisjunction, Genetic | 1 | 2025 | 18 | 0.230 |
Why?
|
| Crossing Over, Genetic | 1 | 2025 | 53 | 0.230 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2025 | 20 | 0.230 |
Why?
|
| Superoxide Dismutase | 1 | 2026 | 179 | 0.230 |
Why?
|
| Chromosome Segregation | 1 | 2025 | 71 | 0.230 |
Why?
|
| Acrylamides | 1 | 2025 | 27 | 0.230 |
Why?
|
| Follow-Up Studies | 10 | 2026 | 5296 | 0.230 |
Why?
|
| Leukapheresis | 1 | 2025 | 14 | 0.230 |
Why?
|
| Retrospective Studies | 16 | 2026 | 17666 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 314 | 0.230 |
Why?
|
| Treatment Outcome | 11 | 2024 | 12964 | 0.220 |
Why?
|
| Trisomy | 1 | 2025 | 112 | 0.220 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.220 |
Why?
|
| Genotype | 6 | 2021 | 2655 | 0.220 |
Why?
|
| Osteosarcoma | 1 | 2008 | 265 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 39 | 0.220 |
Why?
|
| Microfluidics | 1 | 2025 | 30 | 0.220 |
Why?
|
| Immunotherapy | 2 | 2024 | 765 | 0.220 |
Why?
|
| Animals | 16 | 2025 | 34371 | 0.220 |
Why?
|
| Exome | 3 | 2022 | 1076 | 0.210 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 49 | 0.210 |
Why?
|
| Alleles | 4 | 2025 | 1708 | 0.210 |
Why?
|
| Survival Rate | 7 | 2021 | 2151 | 0.210 |
Why?
|
| Mercaptopurine | 3 | 2019 | 72 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 52 | 0.210 |
Why?
|
| PAX5 Transcription Factor | 2 | 2024 | 16 | 0.200 |
Why?
|
| Constipation | 1 | 2024 | 130 | 0.200 |
Why?
|
| Piperidines | 1 | 2025 | 232 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 131 | 0.200 |
Why?
|
| Bone Marrow | 2 | 2022 | 314 | 0.200 |
Why?
|
| Imatinib Mesylate | 2 | 2020 | 47 | 0.190 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 444 | 0.190 |
Why?
|
| Incidence | 7 | 2025 | 3347 | 0.190 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1957 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 134 | 0.190 |
Why?
|
| Immunoglobulins | 1 | 2023 | 159 | 0.190 |
Why?
|
| Lipids | 1 | 2026 | 565 | 0.180 |
Why?
|
| Monocytes | 2 | 2023 | 337 | 0.180 |
Why?
|
| Congenital Abnormalities | 1 | 2025 | 322 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2021 | 750 | 0.180 |
Why?
|
| Leukemia, Myeloid | 2 | 2013 | 80 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 149 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3673 | 0.180 |
Why?
|
| Adult | 14 | 2025 | 31702 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 180 | 0.170 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 722 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 57 | 0.170 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 7 | 0.160 |
Why?
|
| Infant, Newborn | 8 | 2025 | 8588 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 517 | 0.160 |
Why?
|
| Registries | 3 | 2025 | 1599 | 0.160 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 148 | 0.160 |
Why?
|
| Leukocyte Count | 3 | 2025 | 248 | 0.160 |
Why?
|
| Electronic Health Records | 2 | 2024 | 810 | 0.160 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2019 | 18 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 80 | 0.160 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 31 | 0.160 |
Why?
|
| Software | 1 | 2024 | 752 | 0.150 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 79 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 267 | 0.150 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 307 | 0.150 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 21 | 0.150 |
Why?
|
| Cytokines | 1 | 2025 | 1347 | 0.150 |
Why?
|
| Karyotyping | 4 | 2015 | 314 | 0.150 |
Why?
|
| Homozygote | 1 | 2021 | 547 | 0.150 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 30 | 0.150 |
Why?
|
| Social Class | 1 | 2020 | 211 | 0.150 |
Why?
|
| Diploidy | 2 | 2008 | 40 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1405 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2021 | 366 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 193 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2021 | 810 | 0.140 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 70 | 0.140 |
Why?
|
| Biomarkers | 3 | 2026 | 3405 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2020 | 195 | 0.140 |
Why?
|
| Pyrazoles | 2 | 2024 | 358 | 0.140 |
Why?
|
| Maternal Exposure | 1 | 2019 | 149 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 704 | 0.130 |
Why?
|
| Air Pollutants | 1 | 2019 | 126 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 103 | 0.130 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 897 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2017 | 60 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 676 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2022 | 1947 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 551 | 0.120 |
Why?
|
| Genome, Human | 2 | 2021 | 1332 | 0.120 |
Why?
|
| Base Sequence | 2 | 2011 | 2782 | 0.120 |
Why?
|
| Cell Line | 3 | 2013 | 2605 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2021 | 777 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1139 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2020 | 565 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 112 | 0.120 |
Why?
|
| Risk | 2 | 2023 | 739 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2024 | 3695 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 749 | 0.120 |
Why?
|
| Immune Evasion | 1 | 2015 | 39 | 0.120 |
Why?
|
| Smad Proteins | 1 | 2015 | 45 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2017 | 322 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 755 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2015 | 266 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 849 | 0.110 |
Why?
|
| Apoptosis | 2 | 2018 | 1861 | 0.110 |
Why?
|
| Dexamethasone | 3 | 2021 | 261 | 0.110 |
Why?
|
| DNA | 1 | 2020 | 1442 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2024 | 5123 | 0.100 |
Why?
|
| Texas | 5 | 2022 | 3615 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 1078 | 0.100 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 405 | 0.100 |
Why?
|
| Dendritic Cells | 2 | 2013 | 438 | 0.100 |
Why?
|
| Age Factors | 3 | 2021 | 2872 | 0.100 |
Why?
|
| Cytosol | 1 | 2013 | 140 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 344 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 894 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2025 | 1894 | 0.100 |
Why?
|
| Electronics | 2 | 2023 | 45 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 36 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 570 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 463 | 0.100 |
Why?
|
| Logistic Models | 3 | 2026 | 1831 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 429 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 684 | 0.090 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 154 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 358 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 1001 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 136 | 0.090 |
Why?
|
| Cellulitis | 1 | 2011 | 62 | 0.090 |
Why?
|
| Janus Kinase 3 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 435 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2023 | 286 | 0.090 |
Why?
|
| Creatinine | 2 | 2023 | 402 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 739 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 421 | 0.080 |
Why?
|
| Immunophenotyping | 3 | 2019 | 336 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 306 | 0.080 |
Why?
|
| DNA Primers | 1 | 2011 | 609 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 295 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1258 | 0.080 |
Why?
|
| Neutropenia | 1 | 2011 | 205 | 0.080 |
Why?
|
| Nitriles | 2 | 2024 | 165 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Prednisone | 2 | 2020 | 244 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1521 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 989 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 54 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 549 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 101 | 0.080 |
Why?
|
| Asparaginase | 2 | 2020 | 51 | 0.080 |
Why?
|
| Vincristine | 2 | 2021 | 194 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 312 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 703 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 530 | 0.070 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 245 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2023 | 769 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2018 | 69 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 589 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2024 | 443 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 693 | 0.060 |
Why?
|
| Gene Editing | 2 | 2021 | 229 | 0.060 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 368 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 650 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 1235 | 0.060 |
Why?
|
| United States | 4 | 2026 | 11800 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2008 | 605 | 0.060 |
Why?
|
| Cell Survival | 1 | 2008 | 853 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2564 | 0.060 |
Why?
|
| Meiosis | 1 | 2025 | 112 | 0.060 |
Why?
|
| Markov Chains | 1 | 2025 | 100 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2025 | 46 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1488 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4769 | 0.060 |
Why?
|
| Data Curation | 1 | 2024 | 14 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1346 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2025 | 4683 | 0.060 |
Why?
|
| Cell Separation | 1 | 2025 | 222 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2008 | 864 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2120 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 1788 | 0.050 |
Why?
|
| Haplotypes | 1 | 2025 | 543 | 0.050 |
Why?
|
| Leukocytes | 1 | 2025 | 211 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 203 | 0.050 |
Why?
|
| France | 1 | 2023 | 89 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 22 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2023 | 31 | 0.050 |
Why?
|
| Oncogenes | 1 | 2004 | 164 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2023 | 13 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 237 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 1745 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 40 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1151 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2297 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 460 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 685 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1008 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2390 | 0.040 |
Why?
|
| Entropy | 1 | 2021 | 28 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2021 | 34 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 375 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 7 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 39 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 40 | 0.040 |
Why?
|
| Transcriptome | 2 | 2019 | 1163 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2020 | 34 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 361 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1617 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 29 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 996 | 0.040 |
Why?
|
| Sepsis | 1 | 2024 | 501 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2021 | 252 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 132 | 0.040 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 595 | 0.040 |
Why?
|
| Luciferases | 1 | 2019 | 127 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 43 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 110 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 51 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 115 | 0.040 |
Why?
|
| Mucositis | 1 | 2019 | 19 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 224 | 0.040 |
Why?
|
| Seizures | 1 | 2024 | 889 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 272 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2018 | 3864 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 149 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 781 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 115 | 0.040 |
Why?
|
| Prevalence | 1 | 2026 | 2694 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 298 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 246 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 3460 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2025 | 556 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 117 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 117 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 794 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 373 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1075 | 0.040 |
Why?
|
| Air Pollution | 1 | 2019 | 78 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4516 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 364 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 22 | 0.030 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 22 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 506 | 0.030 |
Why?
|
| Proteome | 1 | 2020 | 286 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 617 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 152 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 203 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 615 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1316 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 611 | 0.030 |
Why?
|
| Guatemala | 1 | 2017 | 64 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 6494 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 23 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 590 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 44 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 186 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 620 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1309 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 283 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 442 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 400 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 872 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 301 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 832 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 709 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 579 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 961 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 310 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 175 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 136 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 2113 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 124 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1686 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 564 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2013 | 32 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 837 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1397 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 97 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 63 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 43 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1989 | 0.020 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 20 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2015 | 515 | 0.020 |
Why?
|
| Myeloblastin | 1 | 2013 | 18 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 759 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2013 | 78 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 133 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 199 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 109 | 0.020 |
Why?
|
| Epilepsy | 1 | 2020 | 889 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 1556 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 714 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1571 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1625 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 665 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 792 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2363 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4696 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 670 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 542 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1405 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 834 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1231 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2143 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1711 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2013 | 502 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1023 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2971 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2986 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2082 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 28883 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 21255 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2004 | 726 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2356 | 0.010 |
Why?
|